313240-72-1 Usage
Uses
Used in Medicinal Chemistry:
4-(Trifluoromethoxy)benzimidamide is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its unique structure and potential biological activities.
Used in Drug Discovery:
4-(Trifluoromethoxy)benzimidamide is used as a lead compound in drug discovery for its potential antiviral, antimicrobial, and anticancer properties, which can be further optimized for therapeutic applications.
Used in Pharmaceutical Industry:
4-(Trifluoromethoxy)benzimidamide is used as a building block for the development of novel bioactive molecules with improved chemical and metabolic stability, enhancing the efficacy and safety of new drugs.
Used in Antiviral Applications:
4-(Trifluoromethoxy)benzimidamide is used as an antiviral agent for its potential to inhibit viral replication and reduce the severity of viral infections.
Used in Antimicrobial Applications:
4-(Trifluoromethoxy)benzimidamide is used as an antimicrobial agent to combat bacterial infections and reduce the risk of antibiotic resistance.
Used in Anticancer Applications:
4-(Trifluoromethoxy)benzimidamide is used as an anticancer agent for its potential to inhibit tumor growth and proliferation, offering a new avenue for cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 313240-72-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,3,2,4 and 0 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 313240-72:
(8*3)+(7*1)+(6*3)+(5*2)+(4*4)+(3*0)+(2*7)+(1*2)=91
91 % 10 = 1
So 313240-72-1 is a valid CAS Registry Number.
313240-72-1Relevant academic research and scientific papers
Identification of NVP-TNKS656: The use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor
Shultz, Michael D.,Cheung, Atwood K.,Kirby, Christina A.,Firestone, Brant,Fan, Jianmei,Chen, Christine Hiu-Tung,Chen, Zhouliang,Chin, Donovan N.,Dipietro, Lucian,Fazal, Aleem,Feng, Yun,Fortin, Pascal D.,Gould, Ty,Lagu, Bharat,Lei, Huangshu,Lenoir, Francois,Majumdar, Dyuti,Ochala, Etienne,Palermo,Pham, Ly,Pu, Minying,Smith, Troy,Stams, Travis,Tomlinson, Ronald C.,Touré, B. Barry,Visser, Michael,Wang, Run Ming,Waters, Nigel J.,Shao, Wenlin
, p. 6495 - 6511 (2013/09/23)
Tankyrase 1 and 2 have been shown to be redundant, druggable nodes in the Wnt pathway. As such, there has been intense interest in developing agents suitable for modulating the Wnt pathway in vivo by targeting this enzyme pair. By utilizing a combination of structure-based design and LipE-based structure efficiency relationships, the core of XAV939 was optimized into a more stable, more efficient, but less potent dihydropyran motif 7. This core was combined with elements of screening hits 2, 19, and 33 and resulted in highly potent, selective tankyrase inhibitors that are novel three pocket binders. NVP-TNKS656 (43) was identified as an orally active antagonist of Wnt pathway activity in the MMTV-Wnt1 mouse xenograft model. With an enthalpy-driven thermodynamic signature of binding, highly favorable physicochemical properties, and high lipophilic efficiency, NVP-TNKS656 is a novel tankyrase inhibitor that is well suited for further in vivo validation studies.
